Sign in
KZR Stock Price, Chart, Stats & News
Kezar Life Sciences, Inc.
Save
Kezar Life Sciences, Inc. (KZR) does not currently pay a dividend.
53.86M
Market cap
–
Current P/E
–
Forward P/E
KZR chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -80.51% |
ROE | -70.94% |
D/E | 0.03x |
Interest coverage ratio | -63.11x |
KZR valuation
P/E | – |
P/S | – |
P/B | 0.65x |
P/CF | -0.88x |
P/FCF | -0.88x |
P/OCF | -0.88x |
PEG | 0.04x |
EV multiple | -1.93x |
About
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor.
Similar securities
Based on sector and market capitalization
Report issue